Education
About Us
Working with TipRanks
Follow Us
BeiGene Ltd (HK:6160)
:6160
6160 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$85.30 - HK$178.00
Previous CloseN/A
Volume1.62M
Average Volume (3M)6.62M
Market Cap
HK$239.76B
Enterprise ValueHK$20.05B
Total Cash (Recent Filing)HK$2.52B
Total Debt (Recent Filing)$996.83M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Aug 22, 2025EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding1,424,802,000
10 Day Avg. Volume6,791,692
30 Day Avg. Volume6,618,635
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)5.25
Price to Sales (P/S)0.00
P/FCF Ratio-11.72
Enterprise Value/Market Cap0.08
Enterprise Value/Revenue1.39
Enterprise Value/Gross Profit5.66
Enterprise Value/Ebitda-9.86
Forecast
1Y Price Target
HK$197.80Price Target Upside34.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
BeiGene Ltd News
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
2.63%
Mutual Funds
― Other Institutional Investors
92.49% Public Companies and
Individual Investors
6160 FAQ
What was BeiGene Ltd’s price range in the past 12 months?
BeiGene Ltd lowest stock price was HK$85.30 and its highest was HK$178.00 in the past 12 months.
What is BeiGene Ltd’s market cap?
BeiGene Ltd’s market cap is HK$239.76B.
When is BeiGene Ltd’s upcoming earnings report date?
BeiGene Ltd’s upcoming earnings report date is Aug 22, 2025 which is in 53 days.
How were BeiGene Ltd’s earnings last quarter?
BeiGene Ltd released its earnings results on May 07, 2025. The company reported HK$0 earnings per share for the quarter, beating the consensus estimate of -HK$0.351 by HK$0.351.
Is BeiGene Ltd overvalued?
According to Wall Street analysts BeiGene Ltd’s price is currently Undervalued.
Does BeiGene Ltd pay dividends?
BeiGene Ltd does not currently pay dividends.
What is BeiGene Ltd’s EPS estimate?
BeiGene Ltd’s EPS estimate is 0.11.
How many shares outstanding does BeiGene Ltd have?
BeiGene Ltd has 1,424,802,000 shares outstanding.
What happened to BeiGene Ltd’s price movement after its last earnings report?
BeiGene Ltd reported an EPS of HK$0 in its last earnings report, beating expectations of -HK$0.351. Following the earnings report the stock price went down -7.963%.
Which hedge fund is a major shareholder of BeiGene Ltd?
Currently, no hedge funds are holding shares in HK:6160
BeiGene Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$197.80 (34.19% Upside)
HK$197.80 (34.19% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
73.00%
12-Months-Change
Fundamentals
Return on Equity
-11.43%
Trailing 12-Months
Asset Growth
2.46%
Trailing 12-Months
Company Description
BeiGene Ltd
BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Technical Analysis
Innovent Biologics
―
Wuxi Biologics (Cayman)
―
WuXi AppTec Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
―